Safety of Exogenous Recombinant Human Platelet‐Derived Growth Factor‐ BB ( rhPDGF ‐ BB ) for Medical and Cosmetic Applications: A Review
Journal of Cosmetic Dermatology · 2026-01 · 25 (1)
DOI: 10.1111/jocd.70636 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 30.12.2025. Verfasst von Christopher K Hee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lynch Regenerative Medicine, Franklin, Tennessee, USA. Hauptthemen laut MEDLINE: Becaplermin, Cosmetic Techniques, Proto-Oncogene Proteins c-sis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recombinant human platelet‐derived growth factor‐BB (rhPDGF‐BB or pure PDGF) has been extensively studied in medicine, resulting in four FDA approvals for products based on pure PDGF for tissue regeneration applications, including stimulation of the healing of skin wounds in diabetic patients, stimulation of healing of intra‐oral tissue defects, and stimulation of bone and tissue regeneration following foot and ankle arthrodesis surgery. More recently, pure PDGF has also been introduced for esthetic and cosmetic applications.
Objective
Here, we review the extensive nonclinical and clinical pharmacokinetic and safety studies performed on rhPDGF‐BB across diverse administration routes, including topical, injection, and surgical implantation to establish a large margin of safety.
Results
Pharmacokinetic studies confirmed that systemic exposure to rhPDGF‐BB is negligible following repeated topical application, injection, or implantation, minimizing any potential for systemic risks. Biocompatibility and toxicology studies demonstrated that rhPDGF‐BB applied topically to skin, implanted, or injected subcutaneously, intradermally, intramuscularly, intraperitoneally, or intravenously, one time, or repeatedly, is noncytotoxic, nonirritating, nonsensitizing, nonmutagenic, nonclastogenic, noncarcinogenic, and nontoxic. No risk of cancer incidence or cancer mortality was detected following injection, implantation, or repeated, daily topical application of rhPDGF‐BB onto partial or full thickness skin wounds for up to 20 weeks, that is, 140 doses.
Conclusion
The totality of the data demonstrates that the use of rhPDGF‐BB for regeneration and rejuvenation of skin and other tissues has an excellent safety profile, a finding further affirmed by its record of safe and effective use in multiple medical indications for over 25 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lynch Regenerative Medicine, Franklin, Tennessee, USA.
- Chisholm Clinical Research Services, LLC, Ft. Worth, Texas, USA.
ORCID-Profile: Herbert B Slade, Samuel E Lynch
Zitieren
APA
Hee, C. K., Slade, H. B., & Lynch, S. E. (2026). Safety of Exogenous Recombinant Human Platelet‐Derived Growth Factor‐ BB ( rhPDGF ‐ BB ) for Medical and Cosmetic Applications: A Review. Journal of Cosmetic Dermatology, 25(1). https://doi.org/10.1111/jocd.70636
Vancouver
Hee CK, Slade HB, Lynch SE. Safety of Exogenous Recombinant Human Platelet‐Derived Growth Factor‐ BB ( rhPDGF ‐ BB ) for Medical and Cosmetic Applications: A Review. Journal of Cosmetic Dermatology. 2026;25(1). doi:10.1111/jocd.70636
BibTeX
@article{Hee2026,
author = {Hee, Christopher K and Slade, Herbert B and Lynch, Samuel E},
title = {Safety of Exogenous Recombinant Human Platelet‐Derived Growth Factor‐ BB ( rhPDGF ‐ BB ) for Medical and Cosmetic Applications: A Review},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {1},
doi = {10.1111/jocd.70636}
}
EUVIMED